BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2026

Conditions

Ovarian Cancer

Interventions

BEHAVIORAL

Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer

All Listed Sponsors

lead

Assiut University

OTHER

NCT06304922 - BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary | Biotech Hunter | Biotech Hunter